About
Technology
Issues
FAQ
Links
Official Page
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.